14588-60-4

Usage

Uses

Used in Pharmaceutical Research and Development:
3,5-dimethoxy-4-phenylmethoxy-benzoate is used as a chemical entity in pharmaceutical research and development for its potential pharmacological properties. 3,5-dimethoxy-4-phenylmethoxy-benzoate is being explored for its possible biological activity, which may contribute to the discovery of new therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, 3,5-dimethoxy-4-phenylmethoxy-benzoate is used as a building block for the synthesis of other complex molecules. Its unique structure allows for the creation of a variety of chemical compounds, expanding the scope of organic synthesis.
Used in Material Science:
3,5-dimethoxy-4-phenylmethoxy-benzoate is also utilized in material science, where its structural features may contribute to the development of new materials with specific properties. Its potential applications in this field are currently being investigated to harness its capabilities in creating innovative materials.

InChI:InChI=1/C16H16O5/c1-19-13-8-12(16(17)18)9-14(20-2)15(13)21-10-11-6-4-3-5-7-11/h3-9H,10H2,1-2H3,(H,17,18)

Upstream product

• 100-39-0 benzyl bromide 
• 1916-07-0 3,4,5-trimethoxybenzoic acid methyl ester 
• 530-57-4 3,5-dimethoxy-4-hydroxybenzoic acid 
• 118-41-2 Eudesmic acid 
• 100-44-7 benzyl chloride 
• 884-35-5 methyl syringate 
• 99463-10-2 benzyl 4-(benzyloxy)-3,5-dimethoxybenzoate 
• 27065-65-2 methyl 4-benzyloxy-3,5-dimethoxybenzoate 

Downstream Products

• 14588-61-5 4-benzyloxy-3,5-dimethoxybenzoic acid chloride 
• 3086-85-9 4-benzyloxy-3,5-dimethoxy-benzoic acid amide 
• 86978-66-7 anhydride of 4-benzyloxy-3,5-dimethoxybenzoic acid 
• 2176-18-3 4-benzyloxy-3,5-dimethoxybenzyl alcohol 
• 1195777-18-4 4-benzyloxy-3,5-dimethoxybenzoic acid 5-chloro-2-butyl-3-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazol-4-yl methyl ester 
• 1262152-98-6 4-benzyloxy-3,5-dimethoxy benzoic acid-3-(1,2,3-tri-tert-butoxycarbonyl-3-(2 mercaptoethyl)guanidino)propyl ester 
• 1427191-33-0 C₃₈H₅₅N₃O₁₁S 
• 1427191-34-1 C₃₉H₅₇N₃O₁₁S 
• 1427191-35-2 C₄₀H₅₉N₃O₁₁S 
• 1427191-36-3 C₄₀H₅₇N₃O₁₁S 
• 1166820-78-5 3-O-(4-hydroxy-3,5-dimethoxybenzoyl)catechin 
• 1166820-76-3 5,7,3',4'4''-penta-O-acetyl-3-O-(3,5-dimethoxybenzoyl)catechin 
• 302968-98-5 (4-benzyloxy-3,5-dimethoxy-phenyl)-[2-(diphenyl-phosphinoyl)-pyrrolidin-1-yl]-methanone 
• 530-57-4 3,5-dimethoxy-4-hydroxybenzoic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of new sesamol-based phenolic acid derivatives with hypolipidemic, antioxidant, and hepatoprotective effects

The objective of this study is to synthesize a series of sesamol-based phenolic acid derivatives, which were designed by combination principle. The hypolipidemic activity of all these compounds was preliminarily screened by acute hyperlipidemic mice model induced by Triton WR 1339, in which compound T6 exhibited more significant reducing plasma TG and TC than fenofibrate. Compound T6 was also found to obviously decrease TG and TC both in the plasma and hepatic tissue of high-fat-diet-induced hyperlipidemic mice. Moreover, T6 showed hepatoprotective effects, which remarkable amelioration in characteristic liver enzymes was examined and the histopathological observation displayed that compound T6 inhibited lipids accumulation in the hepatic. The levels of PPAR-α receptor related to lipids metabolism in hepatic tissue were upregulated after T6 treatment. Other potent effects of T6 such as antioxidant and anti-inflammatory activity were also observed. On the bases of these findings, compound T6 may serve as an effective hypolipidemic and hepatoprotective agent. [Figure not available: see fulltext.]

Herba Leonuri (motherwort) alkali analogs and method for preparation thereof

The invention belongs to the field of medicinal chemistry and in particular relates to a leonurine analog and a preparation method thereof. The leonurine analog provided by the invention has a structure of a formula (1). The preparation method comprises the following steps of: combining a Chinese medicinal monomer with an active gas molecule by using a computer simulation aided design, wherein leonurine serves as a lead compound; and introducing a signal molecule hydrogen sulphide releasing group to a guanidyl of the leonurine, so that controllable release can be realized in vivo and unique double protective action of the traditional Chinese medicinal monomer and the active gas molecule can be exerted. A primary test shows that the prepared leonurine has protective action on myocardial ischemia in vitro and in vivo and can be further used for preparing a medicament for treating heart cerebrovascular diseases. In the formula, m is 1 to 6 and n is 2 to 3.

Benzoic hydroxamate-based iron complexes as model compounds for humic substances: Synthesis, characterization and algal growth experiments

A series of monomeric and dimeric FeIII complexes bearing benzoic hydroxamates as O,O-chelates has been prepared and characterized by elemental analysis, IR spectroscopy, UV-Vis spectroscopy, electrospray ionization mass spectrometry (ESI-MS), cyclic voltammetry, EPR spectroscopy and for some examples by X-ray diffraction analysis. The stability of the synthesized complexes in pure water and seawater was monitored over 24 h by means of UV-Vis spectrometry. The ability to release iron from the synthesized model complexes has been investigated with algae growth experiments.

NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF

Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF

Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES

The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.

1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.

Factors influencing the antifolate activity of synthetic tea-derived catechins

Novel tea catechin derivatives have been synthesized, and a structure-activity study, related to the capacity of these and other polyphenols to bind dihydrofolate reductase (DHFR), has been performed. The data showed an effective binding between all molecules and the free enzyme, and the dissociation constants of the synthetic compounds and of the natural analogues were on the same order. Polyphenols with a catechin configuration were better DHFR inhibitors than those with an epicatechin configuration. Antiproliferative activity was also studied in cultured tumour cells, and the data showed that the activity of the novel derivatives was higher in catechin isomers. Derivatives with a hydroxyl group para on the ester-bonded gallate moiety presented a high in vitro binding to DHFR, but exhibited transport problems in cell culture due to ionization at physiologic pHs. The impact of the binding of catechins to serum albumin on their biological activity was also evaluated. The information provided in this study could be important for the design of novel medicinal active compounds derived from tea catechins. The data suggest that changes in their structure to avoid serum albumin interactions and to facilitate plasmatic membrane transport are essential for the intracellular functions of catechins.

Synthesis, radical scavenging activity, protection during storage, and frying by novel antioxidants

Novel antioxidants, derivatives of trolox, and selected phenolic acids have been prepared in good yields and fully characterized by 1H NMR, 13C NMR, and MS. Their antioxidant activities have been assessed by DPPH and ORAC assays, and during frying and accelerated storage tests. Novel phenolic compounds exhibited higher radical scavenging activities than both trolox and R-tocopherol. Trolox hydroxybenzoate showed a significantly higher protection than R-tocopherol under storage conditions. All new antioxidants performed better than R-tocopherol under frying conditions. Moreover, their outstanding thermal stability makes them more valuable than R-tocopherol for frying applications.

Losartan-antioxidant hybrids: Novel molecules for the prevention of hypertension-induced cardiovascular damage

We report the first examples of a new series of antioxidant-sartan hybrids (AO-sartans), which were made by adding an antioxidant fragment to the hydroxymethyl side chain of losartan. Experiments performed in cultured cells demonstrate that these new hybr